Perspective Therapeutics, Inc. (NYSE:CATX) CEO Acquires $54,810.00 in Stock

Perspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor bought 14,500 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were purchased at an average cost of $3.78 per share, for a total transaction of $54,810.00. Following the acquisition, the chief executive officer now directly owns 152,072 shares in the company, valued at $574,832.16. This trade represents a 10.54 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Perspective Therapeutics Stock Performance

CATX stock opened at $4.12 on Thursday. Perspective Therapeutics, Inc. has a 52 week low of $2.28 and a 52 week high of $19.05. The firm’s fifty day simple moving average is $10.96.

Perspective Therapeutics (NYSE:CATX) last released its earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The company had revenue of $0.37 million for the quarter. Research analysts expect that Perspective Therapeutics, Inc. will post -0.87 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CATX. UBS Group initiated coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $20.00 target price on the stock. Wedbush reissued an “outperform” rating and issued a $11.00 price target (down previously from $20.00) on shares of Perspective Therapeutics in a report on Thursday, November 21st. Truist Financial initiated coverage on shares of Perspective Therapeutics in a report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Finally, Oppenheimer decreased their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, November 22nd. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $15.14.

Hedge Funds Weigh In On Perspective Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. nVerses Capital LLC purchased a new stake in Perspective Therapeutics during the 3rd quarter valued at $57,000. US Bancorp DE boosted its position in Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after buying an additional 3,866 shares during the period. Victory Capital Management Inc. purchased a new stake in Perspective Therapeutics during the 2nd quarter valued at $117,000. Point72 DIFC Ltd purchased a new stake in Perspective Therapeutics during the 2nd quarter valued at $118,000. Finally, Intech Investment Management LLC purchased a new stake in Perspective Therapeutics during the 3rd quarter valued at $137,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.